PRA Health Sciences Inc (NASDAQ:PRAH) Given Average Rating of “Hold” by Brokerages

PRA Health Sciences Inc (NASDAQ:PRAH) has earned a consensus recommendation of “Hold” from the fourteen research firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $113.00.

Several research analysts have commented on the stock. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Wolfe Research began coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. ValuEngine raised shares of Yandex from a “hold” rating to a “buy” rating in a research note on Saturday, April 13th. Leerink Swann raised shares of AbbVie to a “buy” rating in a research note on Tuesday, July 2nd. Finally, Svb Leerink reissued a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd.

Shares of NASDAQ:PRAH traded down $1.60 during midday trading on Wednesday, hitting $102.06. The company’s stock had a trading volume of 10,873 shares, compared to its average volume of 398,927. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.90 and a current ratio of 0.90. The business’s 50 day moving average is $98.37. PRA Health Sciences has a 12-month low of $82.12 and a 12-month high of $121.98. The stock has a market cap of $6.64 billion, a P/E ratio of 25.94, a P/E/G ratio of 1.37 and a beta of 1.12.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.15. The business had revenue of $722.00 million for the quarter, compared to the consensus estimate of $730.84 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.85 EPS. Sell-side analysts forecast that PRA Health Sciences will post 4.63 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of PRAH. Dimensional Fund Advisors LP grew its stake in PRA Health Sciences by 1.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 447,357 shares of the medical research company’s stock valued at $41,134,000 after acquiring an additional 6,803 shares in the last quarter. Stifel Financial Corp lifted its stake in PRA Health Sciences by 40.8% in the fourth quarter. Stifel Financial Corp now owns 2,783 shares of the medical research company’s stock valued at $258,000 after buying an additional 807 shares during the period. Thrivent Financial for Lutherans lifted its stake in PRA Health Sciences by 7.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 14,975 shares of the medical research company’s stock valued at $1,377,000 after buying an additional 1,068 shares during the period. Legal & General Group Plc lifted its stake in PRA Health Sciences by 8.1% in the fourth quarter. Legal & General Group Plc now owns 65,231 shares of the medical research company’s stock valued at $5,999,000 after buying an additional 4,877 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in shares of PRA Health Sciences by 82.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 44,054 shares of the medical research company’s stock worth $4,051,000 after purchasing an additional 19,931 shares during the period. 99.75% of the stock is currently owned by hedge funds and other institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Portfolio Manager

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.